Wijkstrom Joakim's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Mar 6, 2023
- Accession no.
- 0001209191-23-016463
- Filed
- Mar 6, 2023
- Trade date
- Mar 2-3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $74.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wijkstrom JoakimCIK 0001785888 | Officer (SVP, Chief Marketing Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Common Stock | SSaleDisposed | −7,720 | $6.23 | −$48,095.6 | 121,653 | Direct | |
| Mar 3, 2023 | Common Stock | SSaleDisposed | −4,113 | $6.32 | −$25,994.16 | 117,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.